New pill (GFH375) vs chemo for KRAS G12D lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new pill (GFH375) against a standard chemotherapy (docetaxel) for advanced lung cancer with a specific KRAS G12D mutation. If you have already tried platinum chemo and an immunotherapy, this trial might offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread or cannot be removed with surgery.
- Your cancer has a specific genetic change called KRAS G12D mutation (your doctor can test for this).
- You have already tried at least one round of platinum chemotherapy and one immunotherapy (like Keytruda or Opdivo), but it stopped working or caused too many side effects.
- You have not been treated before with docetaxel (a chemotherapy drug) or any drug that targets KRAS G12D or pan-KRAS.
- Your cancer does not have other major gene changes (like EGFR, ALK, or additional RAS mutations), and it has not spread to your brain or spine in a way that causes symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted pill (JMKX001899) against a standard chemotherapy drug (docetaxel) for people whose non-small cell lung cancer has a specific gene change called KRAS G12C and has already been treated with chemo and immunotherapy. The goal is to see if the new pill slows the cancer better or has fewer side effects.
This trial tests two pills together (GH21 and D-1553) for people whose cancer has a specific genetic marker called KRAS G12C. The goal is to see if this combination can shrink tumors or slow cancer growth, especially after other treatments have stopped working.
This trial tests a new targeted pill (GFH375) alone or with another drug for people with a specific gene change (KRAS G12D) in advanced lung cancer. It aims to shrink or slow the cancer, possibly better than current standard treatments.
This trial compares a new targeted pill (D-1553) against a standard chemotherapy (docetaxel) for people with a specific type of advanced lung cancer (KRAS G12C mutation) whose cancer has stopped responding to first-line immunotherapy and chemotherapy.
This trial tests a new targeted pill (HS-10370) combined with standard chemotherapy, with or without an immunotherapy drug (adebrelimab), versus another standard treatment (tislelizumab plus chemotherapy) as the first treatment for advanced lung cancer with a KRAS G12C mutation. The goal is to see if the new combination works better and is safe.
This trial tests a new pill (setidegrasib) against a standard chemo drug (docetaxel) for people with a specific type of advanced lung cancer that has a KRAS G12D mutation. The goal is to see which treatment works better.
Hear when a new KRAS G12D Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.